examining plasma vs. csf p-tau217 in preclinical and prodromal alzheimer’s disease
Published 3 months ago • 106 plays • Length 5:19Download video MP4
Download video MP3
Similar videos
-
4:32
plasma tau217 occupancy as accurate as validated csf tests
-
2:20
the ability of plasma p-tau231 to detect preclinical alzheimer’s disease
-
1:32
investigating novel plasma-based p-tau biomarkers
-
2:47
latest knowledge on plasma p-tau in alzheimer’s disease
-
4:07
plasma versus neuroimaging biomarkers for alzheimer’s disease clinical trials
-
2:51
association of csf and plasma biomarkers with longitudinal tau accumulation
-
2:57
the potential of plasma biomarkers in dementia
-
3:09
head-to-head comparison of p-tau species for alzheimer’s disease detection in a real-world cohort
-
2:11
upcoming plasma biomarkers for alzheimer’s disease: aβ, p-tau and gfap
-
1:36
using plasma biomarkers in the diagnosis of alzheimer’s disease
-
1:58
the value of plasma p-tau181 as a screening and diagnostic tool for alzheimer’s disease
-
1:23
plasma biomarkers for alzheimer's disease as pre-screening tools
-
1:14
plasma tau levels and alzheimer’s disease: what’s the relationship?
-
1:17
therapeutic targeting of trem2 in alzheimer’s disease
-
0:41
promising pathways of blood biomarkers: real-world impact of bio-hermes study
-
1:24
markers of of tau pathology in alzheimer’s disease
-
1:18
biomarkers in dementia with lewy bodies: αsyn rt-quic
-
0:56
blood-based biomarkers for treatment monitoring in alzheimer’s disease
-
2:26
the use of csf biomarkers in the diagnosis of alzheimer's disease